In one paragraphArticle in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
7 authors.
Virginio García-LópezDepartment of Medical and Surgical Therapeutics, Division of Clinical Pharmacology, School of Medicine, University of Extremadura, 06006 Badajoz, Spain.ORCID 0000-0003-1489-7296 Carmen López-SánchezDepartment of Human Anatomy and Embryology, Faculty of Medicine and Health Sciences, Institute of Molecular Pathology Biomarkers, University of Extremadura, 06006 Badajoz, Spain.ORCID 0000-0003-3296-2071 Joana PoejoInstitute of Molecular Pathology Biomarkers, University of Extremadura, 06006 Badajoz, Spain.ORCID 0000-0001-8740-1074 Ricardo LagoaSchool of Technology and Management, Polytechnic Institute of Leiria, Morro do Lena, Alto do Vieiro, 2411-901 Leiria, Portugal.ORCID 0000-0003-2375-6612 Dorinda Marques-da-SilvaSchool of Technology and Management, Polytechnic Institute of Leiria, Morro do Lena, Alto do Vieiro, 2411-901 Leiria, Portugal.ORCID 0000-0003-0460-5421 Virginio García-MartínezDepartment of Human Anatomy and Embryology, Faculty of Medicine and Health Sciences, Institute of Molecular Pathology Biomarkers, University of Extremadura, 06006 Badajoz, Spain.ORCID 0000-0002-7760-1985 Carlos Gutierrez-MerinoInstitute of Molecular Pathology Biomarkers, University of Extremadura, 06006 Badajoz, Spain.ORCID 0000-0003-3673-7007 Funding
Government of Extremadura. FEDER co-financing GR24140 (CTS005)LSRE-LCM and ALiCE centers, supported by Fundação para a Ciência e a Tecnologia, I.P. /MCTES Portugal UID/50020/2025 (DOI: 10.54499/UID/50020/2025) and LA/P/0045/2020 (DOI: 10.54499/LA/P/0045/2020)
6 · The paper itselfAbstract
The 3-nitropropionic acid (NPA) promotes neurological alterations in the
Indexed as
Amyloid beta-PeptidesCerebellumKaempferolsNeuroprotective AgentsNitro CompoundsPropionatestau ProteinsAnimalsMalePhosphorylationRatsRats, Wistar3-nitropropionic acidAmyloid beta-PeptideskaempferolKaempferolsNeuroprotective AgentsNitro CompoundsPropionatestau Proteins3-nitropropionic acidA1-type astrocytesamyloid βantihemorrhagic actioncerebellumkaempferolphosphorylated tau
Identifiers
PMID41898739
PMCPMC13026571
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390